Table 3.
Association Between Aspirin Use and CHD Events, Stratified by Lipoprotein(a) Level, in Propensity‐Matched Cohort
| Lipoprotein(a) ≤50 mg/dL (n=1760) | Lipoprotein(a) >50 mg/dL (n=423) | |
|---|---|---|
| CHD events | 156 | 58 |
| HR | 95% CI | P value | HR | 95% CI | P value | |
|---|---|---|---|---|---|---|
| Aspirin use | ||||||
| Unadjusted | 0.89 | 0.65–1.22 | 0.48 | 0.65 | 0.39–1.09 | 0.10 |
| Model 1 | 0.80 | 0.59–1.10 | 0.18 | 0.62 | 0.37–1.06 | 0.08 |
| Model 2 | 0.80 | 0.58–1.10 | 0.17 | 0.54 | 0.31–0.93 | 0.03 |
Model 1 adjusts for sex, race/ethnicity and site. Model 2 adjusts for Model 1+diabetes, hypertension treatment, cigarette smoking, systolic blood pressure, high‐density lipoprotein, total cholesterol, statin use, body mass index, family history of atherosclerotic cardiovascular disease, and C‐reactive protein. CHD indicates coronary heart disease; and HR, hazard ratio.